Plasma chromogranin A: clinical implication in hormone refractory prostate cancer patients receiving docetaxel therapy

被引：0
|
作者：
Mandal, Arup K.
Sarkar, Debansu
Prasad, Rajendra
Agarwal, M. M.
Mete, U. K.
Singh, S. K.
机构：
来源：
INTERNATIONAL JOURNAL OF UROLOGY | 2010年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A140 / A140
页数：1
相关论文
共 50 条
  • [21] Docetaxel plus prednisone in patients with metastatic hormone-refractory prostate cancer: an Italian clinical experience
    Cicero, G.
    De Luca, R.
    [J]. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2011, 15 (03) : 325 - 331
  • [22] Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone
    Caffo, Orazio
    Sava, Teodoro
    Comploj, Evi
    Giampaolo, Maria Anna
    Segati, Romana
    Valduga, Francesco
    Cetto, Gianluigi
    Galligioni, Enzo
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2010, 28 (02) : 152 - 156
  • [23] Docetaxel and zoledronic acid in patients with metastatic hormone-refractory prostate cancer
    Vordos, D
    Paule, B
    Vacherot, F
    Allory, Y
    Salomon, L
    Hoznek, A
    Yiou, R
    Chopin, D
    Abbou, CC
    de la Taille, A
    [J]. BJU INTERNATIONAL, 2004, 94 (04) : 524 - 527
  • [24] Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer
    Younis, Islam R.
    George, Daniel J.
    McManus, Terence J.
    Hurwitz, Herbert
    Creel, Patricia
    Armstrong, Andrew J.
    Yu, Jing Jie
    Bacon, Kristina
    Hobbs, Gerald
    Peer, Cody J.
    Petros, William P.
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (05) : 991 - 997
  • [25] Clinical pharmacology of an atrasentan and docetaxel regimen in men with hormone-refractory prostate cancer
    Islam R. Younis
    Daniel J. George
    Terence J. McManus
    Herbert Hurwitz
    Patricia Creel
    Andrew J. Armstrong
    Jing Jie Yu
    Kristina Bacon
    Gerald Hobbs
    Cody J. Peer
    William P. Petros
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 73 : 991 - 997
  • [26] Phase II study of docetaxel and thalidomide in Japanese patients with prostate cancer refractory to hormone and DEC (docetaxel, estramustine phosphate, and carboplatin) therapy
    Honda, Satoshi
    Inoue, Keita
    Kobara, Chiaki
    Arichi, Naoko
    Mitsui, Yozo
    Hiraoka, Takeo
    Wake, Koji
    Sumura, Masahiro
    Yasumoto, Hiroaki
    Shiina, Hiroaki
    Igawa, Mikio
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2010, 17 : A294 - A295
  • [27] Independent prognostic role of circulating chromogranin A in prostate cancer patients with hormone-refractory disease
    Berruti, A
    Mosca, A
    Tucci, M
    Terrone, C
    Torta, M
    Tarabuzzi, R
    Russo, L
    Cracco, C
    Bollito, E
    Scarpa, RM
    Angeli, A
    Dogliotti, L
    [J]. ENDOCRINE-RELATED CANCER, 2005, 12 (01) : 109 - 117
  • [28] Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
    Sinibaldi, Victoria J.
    [J]. CLINICAL INTERVENTIONS IN AGING, 2007, 2 (04) : 555 - 560
  • [29] Weekly docetaxel for advanced hormone-refractory prostate cancer
    Pepe, A.
    Usset, A.
    Calabria, C.
    Savio, G.
    Palmisano, V.
    Leonardi, V.
    Laudani, A.
    Arcuri, C.
    Giresi, A.
    Agostara, B.
    [J]. ANNALS OF ONCOLOGY, 2006, 17 : VII154 - VII154
  • [30] Significance of docetaxel in the chemotherapy of hormone-refractory prostate cancer
    Wolff, JM
    [J]. ONKOLOGIE, 2003, 26 : 37 - 40
12345